The efficiency of anti-PD-1 or PD-L1 therapy can be improved under pyroptosis-induced inflammation in the tumor microenvironment by chemotherapy, radiotherapy, and other therapeutic regimens (Bergsbaken et al., 2009; Reck et al., 2019). This evidence concerns the gene CD274 and neoplasm.